Form 8-K - Current report:
SEC Accession No. 0001628280-25-043290
Filing Date
2025-10-01
Accepted
2025-10-01 07:06:28
Documents
14
Period of Report
2025-10-01
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cccc-20251001.htm   iXBRL 8-K 30398
2 EX-99.1 cccc-20251001xexx991.htm EX-99.1 11697
6 c4tlogo1.jpg GRAPHIC 8913
  Complete submission text file 0001628280-25-043290.txt   178493

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cccc-20251001.xsd EX-101.SCH 1829
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cccc-20251001_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cccc-20251001_pre.xml EX-101.PRE 13088
16 EXTRACTED XBRL INSTANCE DOCUMENT cccc-20251001_htm.xml XML 2915
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

EIN.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39567 | Film No.: 251362549
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)